| Literature DB >> 35268073 |
Narjara Gonzalez Suarez1, Yuniel Fernandez-Marrero2, Sima Torabidastgerdooei1, Borhane Annabi1.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) cells secretome induces a pro-inflammatory microenvironment within the adipose tissue, which hosts both mature adipocytes and adipose-derived mesenchymal stem/stromal cells (ADMSC). The subsequent acquisition of a cancer-associated adipocyte (CAA)-like phenotype is, however, unknown in ADMSC. While epidemiological studies suggest that consuming a polyphenol-rich diet reduces the incidence of some obesity-related cancers, the chemopreventive impact of green tea-derived epigallocatechin-3-gallate (EGCG) against the cues that trigger the CAA phenotype remain undocumented in ADMSC.Entities:
Keywords: EGCG; EMT; IL-6; Snail; TNBC; pre-adipocytes
Mesh:
Substances:
Year: 2022 PMID: 35268073 PMCID: PMC8912398 DOI: 10.3390/nu14051099
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Transcriptomic modulation of ADMSC(adipose-derived mesenchymal stem/stromal cells) response to variations of the TNBC cell secretome. Human pre-adipocytes mesenchymal stem/stromal cells (ADMSC) were incubated for 24 h with serum-free media conditioned for 48 h by TNBC-derived MDA-MB-231 cells (TNBC cells secretome) in the presence of 10 μM EGCG(epigallocatechin gallate) or Ethanol (vehicle). Total RNA was extracted from triplicate samples, and gene expression modulation was assessed through RNA-Seq analysis, as described in the Methods section. (A) Fold change gene expression compared to control cells considered below the significant threshold (FDR < 0.05) in the presence or absence of EGCG. (B) KEGG pathways enrichment analysis of differentially expressed genes (DEGs) with an absolute fold change (FC) > 2 and adjusted p-value < 0.001 in each experimental condition. (C) Network graph showing enriched pathways and their respective DEGs in the absence of EGCG. Upregulated and downregulated genes are color-coded in green and red, respectively. (D) Expression of selected genes associated with cancer-associated adipocyte (CAA) phenotype and immunomodulation was confirmed by RT-qPCR, as described in the Methods section using a Human Cancer Inflammation and Immunity Crosstalk RT2-Profiler gene array kit. (E) Venn diagram showing the number of DEGs in each experimental condition, followed by a robust k-means clustering visualized as a heatmap. Number of genes per cluster is shown in parenthesis. Representative genes shared in both conditions with a log2FC > 2 and p-value < 0.001. CCL20 (C-C motif ligand 20); CXCL8 and CXCL5 (C-X-C Motif Chemokine Ligand 8 and 5); IL-1β and IL-6 (interleukin 1 beta and 6); COX2 (cyclooxygenase 2); CCL5 and CCL2 (chemokine C-C motif ligand 5 and 2); VEGFa (vascular endothelial growth factor alpha); IDO (indoleamine 2,3-dioxygenase); HIF1a (hypoxia inducible factor 1 alpha) and PD-L1 (programmed death-ligand 1).
The effect of EGCG(epigallocatechin gallate) over Cluster 5 genes upregulated by the TNBC secretome.
| ENSEMBL | Gene | Fold Change | Fold Change | Gene Description | Enriched Terms by KEGG Analysis |
|---|---|---|---|---|---|
| ENSG00000122641 | INHBA | 5.36 | −2.51 | Follicle-Stimulating Hormone-Releasing Protein/secreted |
TGF-beta signaling pathway Signaling pathways regulating pluripotency of stem cells Cytokine-cytokine receptor interaction Associated with cancer cachexia in human patients |
| ENSG00000152952 | PLOD2 | 4.51 | −4.00 | 2 procollagen-lysine/cisternae of the RER. |
Collagen formation and degradation of the extracellular matrix Oxidoreductase activity |
| ENSG00000170961 | HAS2 | 4.25 | −2.99 | Hyaluronan synthase 2 |
Glycosaminoglycan metabolism Hyaluronan synthase activity |
| ENSG00000105835 | NAMPT | 3.94 | −1.54 | Nicotinamide phosphoribosyltransferase; enzime |
NOD-like receptor signaling pathway Cytokine with immunomodulating properties Adipokine with anti-diabetic properties Stress response |
| ENSG00000104321 | TRPA1 | 3.87 | −4.76 | Transient receptor potential cation channel, subfamily a/transmembrane proteins |
Regulation of TRP channels Signal transduction Growth control |
| ENSG00000112972 | HMGCS1 | 3.73 | −2.37 | 3-α-hydroxy-3-methylglutaryl-coa synthase 1/ |
PPAR signaling pathway Terpenoid backbone biosynthesis Cholesterol and lipid homeostasis |
| ENSG00000196611 | MMP1 | 3.68 | −1.80 | Matrix metalloproteinase 1/interstitial collagenase |
PPAR signaling pathway Relaxin signaling pathway Calcium ion binding Metallopeptidase activity |
| ENSG00000067064 | IDI1 | 3.56 | −2.33 | Isopentenyl-diphosphate delta isomerase 1/peroxisomally-localized enzyme |
Terpenoid backbone biosynthesis Regulation of cholesterol biosynthesis mTOR signalling |
| ENSG00000041353 | RAB27B | 3.40 | −6.85 | Member RAS oncogene family/membrane-bound proteins involved in vesicular fusion and trafficking |
Vesicular fusion and trafficking Autophagy pathway and metabolism of proteins GTP binding and protein domain specific binding |
| ENSG00000104415 | CCN4 | 3.39 | −2.87 | Wnt1-inducible signaling pathway protein 1/ |
WNT1 signaling pathway Associated with cell survival |
| ENSG00000157214 | STEAP2 | 3.39 | −2.92 | Six-transmembrane epithelial antigen of prostate/metalloreductase localized in Golgi complex, plasma membrane, and in the cytosol. |
Mineral absorption Transport of glucose and other sugars, bile salts, and organic acids |
| ENSG00000164211 | STARD4 | 3.14 | −2.38 | Start domain-containing protein 4 |
Metabolism of steroid hormones Lipid binding |
| ENSG00000119927 | GPAM | 3.13 | −4.02 | Glycerol-3-phosphate acyltransferase/Mitochondrial |
Regulation of cholesterol biosynthesis and triacylglycerol biosynthesis. Acyltransferase activity |
| ENSG00000120437 | ACAT2 | 3.11 | −2.60 | Acetyl-coa acetyltransferase 2/cytosolic |
Terpenoid backbone biosynthesis Acyltransferase activity |
| ENSG00000171208 | NETO2 | 3.09 | −1.57 | Neuropilin- and tolloid-like 2/transmembrane protein |
Ionotropic glutamate receptor binding in the brain |
| ENSG00000153823 | PID1 | 3.00 | −1.64 | Phosphotyrosine interaction domain-containing 1 |
Proliferation of preadipocytes without affecting adipocytic differentiation |
| ENSG00000153162 | BMP6 | 2.89 | −2.05 | Bone morphogenetic protein 6 |
Secreted ligand of the TGF-beta superfamily of proteins Growth factor activity |
| ENSG00000164647 | STEAP1 | 2.80 | −2.36 | Six-transmembrane epithelial antigen of prostate 1/cell surface antigen significantly expressed at cell-cell junctions. |
Mineral absorption (copper homeostasis) Glucose/energy metabolism Oxidoreductase activity and channel activity |
| ENSG00000135048 | CEMIP2 | 2.76 | −2.24 | Cell migration inducing hyaluronidase 2/transmembrane protein |
Regulator of angiogenesis and VEGF signaling |
| ENSG00000113161 | HMGCR | 2.70 | −2.13 | 3-@hydroxy-3-methylglutaryl-coa reductase/rate-limiting enzyme for cholesterol synthesis |
AMPK signaling pathway Terpenoid backbone biosynthesis. Cholesterol and lipid homeostasis Protein homodimerization activity and NADP binding |
| ENSG00000114251 | WNT5A | 2.70 | −2.10 | Wingless-type mmtv integration site family/secreted signaling proteins |
Wnt signaling pathway Hippo signaling pathway Hepatocellular carcinoma Signaling pathways regulating pluripotency of stem cells Breast Cancer Basal cell carcinoma Cushing syndrome DNA-binding transcription factor activity and protein domain specific binding Oncogenesis |
| ENSG00000182752 | PAPPA | 2.67 | −1.72 | Pregnancy-associated plasma protein/secreted metalloproteinase |
Metabolism of proteins Regulation of Insulin-like Growth Factor (IGF) transport Metalloendopeptidase activity |
| ENSG00000125845 | BMP2 | 2.61 | −2.26 | Bone morphogenetic protein 2/regulatory element: cis-acting enhancer |
Protein heterodimerization activity Cytokine activity |
| ENSG00000144810 | COL8A1 | 2.60 | −2.67 | Collagen, type VIII |
Migration and proliferation of vascular smooth muscle cells |
| ENSG00000140416 | TPM1 | 2.40 | −3.17 | Tropomyosin 1/actin-binding proteins involved in the contractile system of muscles |
Hypertrophic cardiomyopathy Dilated cardiomyopathy Cytoskeletal protein binding |
| ENSG00000068366 | ACSL4 | 2.34 | −5.44 | acyl-coa synthetase long chain family |
PPAR signaling pathway. Lipid biosynthesis and fatty acid degradation |
| ENSG00000140285 | FGF7 | 2.30 | −5.16 | Fibroblast growth factor 7 |
Regulation of actin cytoskeleton Gastric Cancer Breast cancer Rap1 signaling pathway Ras signaling pathway MAPK signaling pathway Melanoma Growth factor activity Chemoattractant activity |
| ENSG00000072274 | TFRC | 2.07 | −2.52 | Transferrin receptor/ |
HIF-1 signaling pathway Receptor-mediated endocytosis Clathrin derived vesicle budding |
| ENSG00000100644 | HIF1A | 2.05 | −5.07 | Hypoxia-inducible factor 1, alpha subunit |
HIF-1 signaling pathway Central carbon metabolism in cancer PD-L1 expression and PD-1 checkpoint pathway in cancer Kaposi sarcoma-associated herpesvirus infectio Th17 cell differentiation Thyroid hormone signaling pathway Proteoglycans in cancer Choline metabolism in cancer Autophagy Renal cell carcinome |
| ENSG00000148848 | ADAM12 | 2.02 | −3.54 | A disintegrin and metalloproteinase domain 12 |
Cell-cell and cell-matrix interactions Metallopeptidase activity |
KEGG: Kyoto Encyclopedia of Genes and Genomes; RER: rough endoplasmic reticulum; NOD: nucleotide-binding oligomerization domain; PPAR: peroxisome proliferator-activated receptors; mTOR: mechanistic target of rapamycin; GTP: guanine nucleotide-binding proteins; WNT1: wingless-type MMTV integration site family, member 1; TGF-beta: transforming growth factor beta; Rap1: Ras-proximate-1; MAPK: mitogen-activated protein kinase.
Figure 2EGCG alters the acquisition of a CAA(cancer-associated adipocyte) phenotype and chemotactic response. (A) ADMSC response to TNBC cells secretome was monitored after 24 h in vehicle-treated cells (white bars), or in the presence of 10 μM EGCG (black bars). Total RNA was isolated, cDNA was synthetized, and CAA genes induction was evaluated using a RT2-Profiler RT-qPCR gene array kit. A representative experiment out of two screens is shown. (B) Relative cell migration rate of ADMSC in response to TNBC cells secretome (CM, closed circles), CM with 30 μM of EGCG (closed triangles), or serum-free negative media (NM, open circles). (C) Basal cell migration response: ADMSC were treated for 24 h with CM (closed circles) or in the presence of CM supplemented 10 μM EGCG (closed triangles); then, basal cell migration was assessed. Data are representative from two independent experiments performed in triplicate. (ND, not detectable). Statistical differences were determined with a Mann–Whitney two tail test with a p < 0.05 (*). CCL5 and CCL2 (chemokine C-C motif ligand 5 and 2); IL-1β and IL-6 (interleukin 1 beta and 6); CXCL8 (C-X-C motif chemokine ligand 8); COX2 (cyclooxygenase 2); VEGFa (vascular endothelial growth factor alpha); IDO (indoleamine 2,3-dioxygenase); HIF1a (hypoxia inducible factor 1 alpha) and PD-L1 (programmed death-ligand 1).
Figure 3EGCG inhibits the induction of the pro-inflammatory cytokine IL-6, epithelial-to-mesenchymal transition (EMT) markers, and NF-κB and Smad2 signal transducing pathways. ADMSC were incubated for 24 h with the TNBC cells secretome and protein lysates collected, as described in the Methods section for Western blotting. (A) Immunoblotting of Snail, Slug, IL-6, and the phosphorylated and total forms of NF-κB and Smad2 (20 μg of protein/well). (B) Representative densitometric analysis of Snail, Slug, IL-6, and the ratio of phosphorylated/total forms of NF-κB and Smad2. Data are expressed as the percent of maximal effect for each marker in ADMSC treated with the TNBC cell secretome (grey bars). Cells treated with negative media (NM, white bars) and TNBC cells secretome in the presence of 10 μM EGCG (black bars). Data are representative of three independent experiments. Snail (Snail family transcriptional repressor 1); Slug (Snail family transcriptional repressor 2); IL-6 (Interleukin 6); NFκβ (nuclear factor κβ); SMAD2 (mothers against decapentaplegic homolog 2); GAPDH (glyceraldehyde 3-phosphate dehydrogenase).
Figure 4Role of Snail in the upregulation of the CAA phenotype genes. Transient gene silencing of Snail (siSnail) or of control (siScrambled) was performed in ADMSC, followed by an incubation with the TNBC cells secretome for 24 h. Cell lysates and total RNA were isolated, and levels of protein and gene expression assessed by Western blotting and RT-qPCR, respectively. (A) Protein levels of Snail and IL-6 were assessed by immunoblotting in ADMSC transfected with siScr or siSnail. (B) Snail gene expression was evaluated by RT-qPCR in ADMSC transfected with siScr or siSnail, and treated with TNBC cell secretome (black bars) or negative media (white bars). (C) CAA gene expression resulting from the comparison of ADMSC transfected with siSnail in response to the TNBC cells secretome vs. siScr cells incubated with the same CM (reference group).
Figure 5Cytokines levels present in the TNBC cells secretome. (A) Human TNBC-derived MDA-MB-231 cells were cultured for 24 h (white bars) and 48 h (black bars) in serum free media, and then their respective secretome collected and the cytokines concentrations determined using an ELISA array as described in the Methods section. (B) IL-6-mediated chemotaxis of ADMSC was assessed in real time, as described in the Methods section using the exCELLigence system (one out of three independent experiments is shown).
Figure 6Role of IL-6 in the ADMSC chemotactic response to the TNBC cells secretome. MDA-MB-231 cells were cultured in serum free media for 48 h and the conditioned media harvested (TNBC cells secretome). (A) Immunoprecipitation (IP) of IL-6 from the TNBC cells secretome was performed as described in the Methods section. The efficiency of the IP was evaluated by immunoblotting of the pellet (P), supernatant (SN), or of the conditioned media before the IP (CM). IgG indicates the heavy chain of the anti-IL-6 antibody used for the IP. (B) Chemotactic response of the ADMSC in response to negative media (open circles), to CM upon control IgG isotype IP (closed circles), or to CM upon anti-IL-6 IP (closed triangles). (C) Transient gene silencing of IL-6 was performed in MDA-MB-231 cells as described in the Methods section. Control cells were transfected with siRNA-Scrambled (siScr). Cells were then serum starved for 24 h. Total RNA was extracted, and RT-qPCR performed to monitor IL-6 silencing efficiency (left). CM was collected to assess secreted IL-6 levels using an ELISA. (D) ADMSC chemotactic response to TNBC cells secretome was monitored in CM harvested from siScr-transfected MDA-MB-231 cells (closed circles), CM harvested from siIL-6-transfected cells (closed triangles), or in response to negative media (NM, open circles). One out of two independent experiments performed in triplicate is shown. Statistical differences were determined with a Mann–Whitney two tail test with a p < 0.05 (*) or p < 0.01(**).
Figure 7IL-6 is not sufficient to trigger the CAA phenotype in ADMSC. (A) ADMSC were incubated for 24 h with negative media (NM), TNBC cell-derived secretome (MDA-MB-231 conditioned media, CM), or 10 pg/mL or 10 ng/mL IL-6 in NM. Cell lysates were next isolated and protein expression of Snail, IL-6, and β-Actin assessed by immunoblotting. (B) Immunoblots showing the phosphorylation status of Smad2 and NF-κB, and the expression of Snail and IL-6 in cells treated with NM, IL-6-IP depleted media (αIL-6), or IgG isotype-IP control media (IgG). Data are representative of one experiment out of two.